

=> d his

(FILE 'HOME' ENTERED AT 14:35:51 ON 15 APR 2003)

FILE 'REGISTRY' ENTERED AT 14:36:00 ON 15 APR 2003

L1 STRUCTURE UPLOADED

L2 50 S L1

L3 2781 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:40:20 ON 15 APR 2003

S L1

FILE 'REGISTRY' ENTERED AT 14:40:25 ON 15 APR 2003

L4 50 S L1

FILE 'CAPLUS' ENTERED AT 14:40:26 ON 15 APR 2003


L5 31 S L4

L6 807 S L3

L7 5 S L6 AND (CEREBROVASCULAR DISORDER# OR CEREBRAL INFARCTION OR T

=> d que 17 stat

L1 STR



Structure attributes must be viewed using STN Express query preparation.

L3 2781 SEA FILE=REGISTRY SSS FUL L1

L6 807 SEA FILE=CAPLUS ABB=ON PLU=ON L3


L7 5 SEA FILE=CAPLUS ABB=ON PLU=ON L6 AND (CEREBROVASCULAR
DISORDER# OR CEREBRAL INFARCTION OR TRANSIENT ISCHEMIC ATTACK
OR TIA OR CEREBRAL APOPLEXY OR CEREBRAL HEMORRHAGE OR SUBARACHN
OID HEMORRHAGE OR CRANIAL HEMORRHAGE OR CEREBROVASCULAR
DEMENTIA OR HYPERTENSIVE ENCEPHALOPATHY)

=> d 1-5 ibib iabs hitstr

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:755214 CAPLUS
 DOCUMENT NUMBER: 137:263024
 TITLE: Preparation of N-isoxazoly biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.
 INVENTOR(S): Murugesan, Natesan; Tellaw, John E.; Macor, Jhon E.; Gu, Zhengxiang
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 206 pp., Cont.-in-part of U.S. Ser. No. 643,640, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002143024	A1	20021003	US 2000-737201	20001214
PRIORITY APPLN. INFO.:			US 1998-91847P	P 19980706
			US 1999-345392	B2 19990701
			US 1999-464037	B2 19991215
			US 2000-481197	B2 20000111
			US 2000-513779	A2 20000225
			US 2000-604322	A2 20000626
			US 2000-643640	B2 20000822

OTHER SOURCE(S): MARPAT 137:263024
 GRAPHIC IMAGE:





ABSTRACT:
 Title compds. (I: R1 = specified oximidazolyl, pyridimidazolyl, pyridylamino, pyridyloxy, triazolyl, quinolinyl, etc.; R2 = H, halo, CHO, (halo)alkyl, pyridyloxy, triazolyl, quinolinyl, etc.; R3 = H, halo, CHO, (halo)alkyl, pyridyloxy, triazolyl, quinolinyl, etc.)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, 3-(2-oxo-1-pyrrolidinyl)propyl ester 254739-83-8P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-, 254739-84-9P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-, 254740-51-7P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254740-52-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, 254740-53-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester 254740-54-0P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 254740-55-1P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254740-56-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-, 254740-57-3P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-, 254740-58-4P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-, 254742-51-3P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl-, 254742-53-5P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester 254742-54-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester 254742-56-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester 254742-58-0P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 3-(2-oxo-1-pyrrolidinyl)propyl ester 254742-67-1P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-, 254742-68-2P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-,
 RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOD (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)



L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)
 cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteroaryl; R101-R104 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, haloalkoxyalkyl, alkoxy, alkoxyalkoxy, cyano, OH, hydroxyalkyl, NO2, etc. with provisos) were prepd. as dual angiotensin II and endothelin receptor antagonists for treatment of hypertension and other diseases (no data). Thus, 4-BrC6H4CH2OH was coupled with [2'-[[[(3,4-dimethyl-3-isoxazolyl)amino]sulfonyl]phenyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66%). This was brominated to give the 4'-bromomethyl deriv. (90%), reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride, and deprotected (49% for two steps) to give 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-[1,1'-biphenyl]-2-sulfonamide.

IT 254738-13-1P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254738-14-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, 254738-15-3P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester 254738-16-4P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 254738-17-5P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester 254738-18-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, 254738-19-7P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-, 254738-20-8P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-, 254739-72-5P, 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl-, 254739-73-6P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester 254739-74-7P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester 254739-75-8P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester 254739-76-9P, 1H-Benzimidazole-7-carboxylic acid,

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 254738-13-1 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)




RN 254738-14-2 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, (9C1) (CA INDEX NAME)




RN 254738-15-3 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254738-16-4 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy]- (9CI) (CA INDEX NAME)




RN 254738-17-5 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 254738-18-6 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A




L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A




RN 254738-19-7 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-, (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 254738-20-0 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-, (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 254739-72-5 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl-, (9CI) (CA INDEX NAME)




RN 254739-73-6 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254739-74-7 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl]-2-phenylethyl ester (9C1) (CA INDEX NAME)





RN 254739-75-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl]-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254739-83-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl ester (9C1) (CA INDEX NAME)



RN 254739-84-9 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A





PAGE 2-A




RN 254739-76-9 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl]-2-(2-oxo-1-pyrrolidinyl)propyl ester (9C1) (CA INDEX NAME)


L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254740-51-7 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl ester (9C1) (CA INDEX NAME)




RN 254740-52-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl ester (9C1) (CA INDEX NAME)




RN 254740-53-9 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl ester (9C1) (CA INDEX NAME)


L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester (9C1) (CA INDEX NAME)




RN 254740-54-0 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- (9C1) (CA INDEX NAME)



RN 254740-55-1 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)




RN 254740-56-2 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9C1) (CA INDEX NAME)




RN 254740-57-3 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9C1) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-58-4 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9C1) (CA INDEX NAME)




RN 254742-51-3 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- (9C1) (CA INDEX NAME)


L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254742-53-5 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester (9C1) (CA INDEX NAME)




RN 254742-54-5 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester (9C1) (CA INDEX NAME)




RN 254742-56-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254742-58-0 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1,3-(2-oxo-1-pyrrolidinyl)propyl ester (9C1) (CA INDEX NAME)




RN 254742-67-1 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9C1) (CA INDEX NAME)


L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254745-58-9 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[[trimethylsilyl]oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9C1) (CA INDEX NAME)



L7 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254742-68-2 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9C1) (CA INDEX NAME)



IT 254745-51-2P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[[trimethylsilyl]oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester
 254745-58-9P, 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[[trimethylsilyl]oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
 RN 254745-51-2 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[2-[[trimethylsilyl]oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS


ACCESSION NUMBER: 2002:551882 CAPLUS
 DOCUMENT NUMBER: 138:214720
 TITLE: Potential for antihypertensive treatment with an ATI-receptor blocker to reduce dementia in the elderly
 AUTHOR(S): Trenkwalder, P.
 CORPORATE SOURCE: Starnberg Hospital, Department of Internal Medicine, Ludwig Maximilian University Munich, Starnberg, Germany
 SOURCE: Journal of Human Hypertension (2002), 16(Suppl. 3), S71-S75
 CODEN: JHYVEN; ISSN: 0950-9240
 PUBLISHER: Nature Publishing Group
 DOCUMENT TYPE: Journal: General Review
 LANGUAGE: English

ABSTRACT:
 A review. Hypertension is an established risk factor for stroke and other ***cerebrovascular*** disorders. Both stroke and small lacunar infarcts or white matter lesions can cause cognitive impairment and dementia, and there is evidence that vascular risk factors play a major role in the development of both Alzheimer's disease and vascular dementia. Several large epidemiol. studies have shown that raised blood pressure in midlife is a strong risk factor for dementia later in life; however, blood pressure often decreases following the development of dementia. The cognitive function hypothesis proposes that elevated blood pressure increases the risk of decline of cognitive function, and that this can be reversed by active lowering of blood pressure. Evidence in support of this hypothesis comes from the Syst-Eur Dementia project, and from a no. of smaller studies. SCOPE (Study on Cognition and Prognosis in the Elderly) is a large prospective study involving almost 5000 elderly patients (age 70-89 yr), who are randomized to receive candesartan cilexetil, 8-16 mg, or placebo. Candesartan was chosen for this study because it is effective and well tolerated in elderly patients. SCOPE should provide important information on the long-term effects of ATI-receptor blocker treatment with candesartan on morbidity-including effects on cognitive function-and cardiovascular mortality in elderly hypertensive patients.

IT 145040-37-5, Candesartan cilexetil
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (potential for antihypertensive treatment with ATI-receptor blocker to reduce dementia in elderly humans)
 RN 145040-37-5 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1-[[[cyclohexyloxy]carbonyl]oxy]ethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:453059 CAPLUS
 DOCUMENT NUMBER: 135:46172
 TITLE: Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.
 INVENTOR(S): Murugesan, Natesan; Tellew, John E.; Macor, John E.; Gu, Zhengxiang
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
 SOURCE: PCT Int. Appl., 287 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044239	A2	20010621	WO 2000-US33730	20001213
WO 2001044239	A3	20011101		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TH
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1237888 A2 20020911 EP 2000-984282 20001213
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SJ, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.:
 US 1999-464037 A 19991215
 US 2000-481197 A 20000111
 US 2000-513779 A 20000225
 US 2000-604322 A 20000626
 US 2000-643640 A 20000822
 WO 2000-US33730 W 20001213

OTHER SOURCE(S): MARPAT 135:46172
 GRAPHIC IMAGE:

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)





ABSTRACT:
 Title compds. (I: R1 = specified oxoimidazolyl, pyridimidazolyl, pyridylamino, triazolyl, quinolinyl, etc.; R2 = H, halo, CHO, (halo)alkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteroaryl; with provisos) were prepd. as dual angiotensin II and endothelin receptor antagonists for treatment of hypertension and other diseases (no data). Thus, 4-Brc6H4CH2OH was coupled with [2-[(4,5-dimethyl-3-isoxazolyl)[(2-methoxyethoxy)methyl]amino]sulfonyl]boronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N'-[2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide (66a). This was brominated to give the 4'-bromomethyl deriv. (90a), reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride, and deprotected (49% for two steps) to give II.



IT 254738-13-1P 254738-14-2P 254738-15-3P
 254738-16-4P 254738-17-5P 254738-18-6P
 254738-19-7P 254738-20-8P 254739-72-5P
 254739-73-6P 254739-74-7P 254739-75-8P
 254739-76-9P 254739-83-8P 254739-84-9P
 254740-51-7P 254740-52-8P 254740-53-9P
 254740-54-0P 254740-55-1P 254740-56-2P
 254740-57-3P 254740-58-4P 254742-51-3P
 254742-53-5P 254742-54-6P 254742-56-8P
 254742-58-0P 254742-67-1P 254742-68-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254738-13-1 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254738-14-2 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)




RN 254738-15-3 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254738-16-4 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl]- (9C1) (CA INDEX NAME)




RN 254738-17-5 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 254738-18-6 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9C1) (CA INDEX NAME)

PAGE 1-A




L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A




RN 254738-19-7 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9C1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 254738-20-0 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)


PAGE 1-A



PAGE 2-A




RN 254739-72-5 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- (9C1) (CA INDEX NAME)




RN 254739-73-6 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254739-74-7 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl]-2-phenylethyl ester (9C1) (CA INDEX NAME)





RN 254739-75-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl]-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254739-83-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl]-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)



RN 254739-84-9 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl]-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A





PAGE 2-A




RN 254739-76-9 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl]-2-(2-oxo-1-pyrrolidinyl)propyl ester (9C1) (CA INDEX NAME)


L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254740-51-7 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl]-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)




RN 254740-52-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl]-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)




RN 254740-53-9 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl]-2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)


L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester (9C1) (CA INDEX NAME)




RN 254740-54-0 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl- (9C1) (CA INDEX NAME)



RN 254740-55-1 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)




RN 254740-56-2 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy- (9C1) (CA INDEX NAME)




RN 254740-57-3 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-58-4 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9C1) (CA INDEX NAME)




RN 254742-51-3 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl- (9C1) (CA INDEX NAME)


L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254742-53-5 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylmethyl ester (9C1) (CA INDEX NAME)




RN 254742-54-6 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester (9C1) (CA INDEX NAME)




RN 254742-56-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[4,5-dimethyl-3-isoxazolyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254742-58-0 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9C1) (CA INDEX NAME)




RN 254742-67-1 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 254745-58-9 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[[2-[[[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl ester (9C1) (CA INDEX NAME)



L7 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254742-68-2 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-3-(2-oxo-1-pyrrolidinyl)propyl ester (9C1) (CA INDEX NAME)



IT 254745-51-2P 254745-58-9P
RL: RCT (Reactant): SPN (Synthetic preparation); PREP (Preparation): RACT (Reactant or reagent)
(prepn. of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254745-51-2 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)[[2-[[[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl ester (9C1) (CA INDEX NAME)




L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:34745 CAPLUS
DOCUMENT NUMBER: 132:93309
TITLE: Preparation of N-isoxazolyl biphenylsulfonamides and related compounds as dual angiotensin II and endothelin receptor antagonists.
INVENTOR(S): Murugesan, Natesan; Tellew, John E.; Macor, John E.; Gu, Zhengxiang
PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: PCT Int. Appl., 283 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200001389	A1	20000113	WO 1999-US15063	19990701
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2336714	AA	20000113	CA 1999-2336714	19990701
AU 9950888	A1	20000124	AU 1999-50888	19990701
EP 1094816	A1	20010502	EP 1999-935406	19990701
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9911621	A	20011016	BR 1999-11621	19990701
EE 200100006	A	20020617	EE 2001-200100006	19990701
JP 2002519380	T2	20020702	JP 2000-557835	19990701
LT 4854	B	20011126	LT 2000-123	20001222
NO 200100062	A	20010305	NO 2001-62	20010105
PRIORITY APPLN. INFO.:			US 1998-91847P	P 19980706
			WO 1999-US15063	W 19990701
OTHER SOURCE(S): MARPAT 132:93309				
GRAPHIC IMAGE:				

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




ABSTRACT:


Title compds. (I; R1 = specified oximidazolyl, pyridoimidazolyl, pyridylamino, triazolyl, quinolinyl, etc.; R2 = H, halo, CHO, alkyl, haloalkyl, cycloalkylalkyl, alkenyl, alkynyl, alkoxyalkyl, alkoxy, cyano, OH, NO2, etc.; R3 = heteroaryl; with provisos), were prep. as dual angiotensin II and endothelin receptor antagonists (no data). Thus, 4-BrC6H4CH2OH was coupled with [2-[[[(4,5-dimethyl-3-isoxazolyl)](2-methoxyethoxy)methyl]amino]sulfonyl]phenylboronic acid to give N-(4,5-dimethyl-3-isoxazolyl)-4'-(hydroxymethyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide. This was brominated to give 4'-bromomethyl-N-(4,5-dimethyl-3-isoxazolyl)-N-[(2-methoxyethoxy)methyl][1,1'-biphenyl]-2-sulfonamide, which reacted with 2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one hydrochloride followed by deprotection to give 4'-[[2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)[1,1'-biphenyl]-2-sulfonamide.

IT 254738-13-1P 254738-14-2P 254738-15-3P
 254738-16-4P 254738-17-5P 254738-18-6P
 254738-19-7P 254738-20-0P 254739-72-5P
 254739-73-6P 254739-74-7P 254739-75-8P
 254739-76-9P 254739-83-8P 254739-84-9P
 254740-51-7P 254740-52-8P 254740-53-9P
 254740-54-0P 254740-55-1P 254740-56-2P
 254740-57-3P 254740-58-4P 254742-51-3P
 254742-53-5P 254742-54-6P 254742-56-8P
 254742-58-0P 254742-67-1P 254742-68-2P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BQL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)
 RN 254738-13-1 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254738-16-4 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester (9C1) (CA INDEX NAME)





RN 254738-17-5 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)



PAGE 1-A



L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254738-14-2 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)



RN 254738-15-3 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester (9C1) (CA INDEX NAME)


L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A




RN 254738-18-6 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9C1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 254738-19-7 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-, methyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 2-A




RN 254738-20-0 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl-3-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)


PAGE 1-A



L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254739-74-7 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-phenylethyl ester (9C1) (CA INDEX NAME)




RN 254739-75-8 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 2-A




RN 254739-72-5 CAPLUS
 CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-N-methyl-3-(2-oxo-1-pyrrolidinyl)ethyl ester (9C1) (CA INDEX NAME)



RN 254739-73-6 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, phenylethyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

PAGE 1-A




PAGE 2-A





RN 254739-76-9 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, 3-(2-oxo-1-pyrrolidinyl)propyl ester (9C1) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)





RN 254739-83-8 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 254739-84-9 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-51-7 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 254740-52-8 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, (9CI) (CA INDEX NAME)


L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254740-53-9 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, methyl ester (9CI) (CA INDEX NAME)




RN 254740-54-0 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]methyl]-2-ethyl-, (9CI) (CA INDEX NAME)




RN 254740-55-1 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, methyl ester (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-56-2 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-, (9CI) (CA INDEX NAME)




RN 254740-57-3 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl][1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-N-methyl-, (9CI) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 254740-58-4 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-[(3,3-dimethyl-2-oxo-1-pyrrolidiny)methyl]](1.1'-biphenyl)-4-yl]methyl]-2-ethoxy-N,N-dimethyl- (9C1) (CA INDEX NAME)




RN 254742-51-3 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl-N-methyl- (9C1) (CA INDEX NAME)


L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)
2-(2-oxo-1-pyrrolidiny)ethyl ester (9C1) (CA INDEX NAME)




RN 254742-58-0 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl-3-(2-oxo-1-pyrrolidiny)propyl ester (9C1) (CA INDEX NAME)




RN 254742-67-1 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethoxy-N-methyl- (9C1) (CA INDEX NAME)




L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 254742-53-5 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl-phenylmethyl ester (9C1) (CA INDEX NAME)




RN 254742-54-6 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl-2-phenylethyl ester (9C1) (CA INDEX NAME)



RN 254742-56-8 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl-2-phenylethyl ester (9C1) (CA INDEX NAME)


L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 254742-68-2 CAPLUS
CN 1H-Benzimidazole-7-carboxamide, 1-[[2'-[[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-2-ethyl-N,N-dimethyl- (9C1) (CA INDEX NAME)




IT 254745-51-2P 254745-58-9P
RL: RCT (Reactant): SPN (Synthetic preparation); PREP (Preparation): RACT (Reactant or reagent)
(prepn. of N-isoxazolyl biphenylsulfonamides and related compds. as dual angiotensin II and endothelin receptor antagonists)

RN 254745-51-2 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)]]2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-ethyl-N-methyl- (9C1) (CA INDEX NAME)



RN 254745-58-9 CAPLUS
CN 1H-Benzimidazole-7-carboxylic acid, 1-[[2'-[[[(3,4-dimethyl-5-isoxazolyl)]]2-[(trimethylsilyl)oxy]ethoxy]methyl]amino]sulfonyl]-2-ethyl-N-methyl- (9C1) (CA INDEX NAME)

L7 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1999:811090 CAPLUS
 DOCUMENT NUMBER: 132:30836
 TITLE: Preventing cerebral infarction through administration of ADP-receptor antiplatelet and antihypertensive drugs in combination
 INVENTOR(S): Configlio, Anthony A.; Plat, Francis R.; Blumenthal, Melvin S.
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl. 20 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965500	A1	19991223	WO 1999-US12934	19990609
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2332608	AA	19991223	CA 1999-2332608	19990609
AU 9945551	A1	20000105	AU 1999-45551	19990609
AU 750122	B2	20020711		
EP 1087775	A1	20010404	EP 1999-928498	19990609
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LT, LU, NL, SE, MC, PT, IE, FI				
US 6248729	B1	20010619	US 1999-328812	19990609
PRIORITY APPLN. INFO.: US 1998-89650P P 19980617				
WO 1999-US12934 W 19990609				


ABSTRACT:

A method is provided for preventing a cerebral infarction by administering to a patient a combination of an ADP-receptor blocking antiplatelet drug, such as clopidogrel, in combination with an antihypertensive agent such as an angiotensin AII antagonist (for example, Irbesartan), an ACE inhibitor (for example, fosinopril) or a NEP/ACE inhibitor such as omapatrilat.


IT 139481-59-7, Candesartan 144701-48-4, Telmisartan
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (preventing cerebral infarction through

L7 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS (Continued)
 administration of ADP-receptor antiplatelet and antihypertensive drugs in combination

RN 139481-59-7 CAPLUS
 CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-[(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl]methyl]- (9CI) (CA INDEX NAME)



RN 144701-48-4 CAPLUS
 CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl)-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (losartan or eprosartan or candesartan (w) cilexetil or candesartan or valsartan or telmisartan or
irbesartan or olmesartan or tasosartan)/cn
PROXIMITY OPERATOR LEVEL NOT CONSISTENT WITH
FIELD CODE - 'AND' OPERATOR ASSUMED 'NDESARTAN (W) CILEXETIL'

1 LOSARTAN/CN
1 EPROSARTAN/CN
1 CANDESARTAN/CN
0 CILEXETIL/CN
1 CANDESARTAN/CN
1 VALSARTAN/CN
1 TELMISARTAN/CN
1 IRBESARTAN/CN
1 OLMESARTAN/CN
1 TASOSARTAN/CN
L8 8 (LOSARTAN OR EPROSARTAN OR CANDESARTAN (W) CILEXETIL OR CANDESAR
TAN OR VALSARTAN OR TELMISARTAN OR IRBESARTAN OR OLMESARTAN OR
TASOSARTAN)/CN

=> s (candesartan cilexetil)/cn
L9 1 (CANDESARTAN CILEXETIL)/CN

=> s 18 or 19
L10 9 L8 OR L9

L10 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 145733-36-4 REGISTRY

CN Pyrido[2,3-d]pyrimidin-7(6H)-one, 5,8-dihydro-2,4-dimethyl-8-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9C1) (CA INDEX NAME)

OTHER NAMES:

CN Tasosartan

CN WAY-ANA 756

FS 3D CONCORD

DR 153042-16-1

MF C23 H21 N7 O

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, DIOGENES, DRUGNL, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MRCK*, MSDS-OHS, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

L10 ANSWER 1 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 4: 137:358120

REFERENCE 5: 137:288447


REFERENCE 6: 137:253025

REFERENCE 7: 137:145599

REFERENCE 8: 137:114551

REFERENCE 9: 137:11000

REFERENCE 10: 136:406900



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

58 REFERENCES IN FILE CA (1962 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

59 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:215317

REFERENCE 2: 138:180405

REFERENCE 3: 137:380012

L10 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 145040-37-5 REGISTRY

CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl] ester (9C1) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, 1-[[[(cyclohexyloxy)carbonyl]oxy]ethyl] ester, (+, -)-

OTHER NAMES:

CN (+, -)-1-Hydroxyethyl 2-ethoxy-1-[p-(o-1H-tetrazol-5-ylphenyl)]-7-benzimidazolecarboxylate, cyclohexyl carbonate (ester)

CN Atacand

CN Candesartan cilexetil

CN TCY 116

CN TCY 116

FS 3D CONCORD

DR 139481-74-6, 198077-85-9

MF C33 H34 N6 O6

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CNB, CHEMCATS, CIN, ODPF, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

L10 ANSWER 2 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

340 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

340 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:231500

REFERENCE 2: 138:214720

REFERENCE 3: 138:210444

REFERENCE 4: 138:163223

REFERENCE 5: 138:158871

REFERENCE 6: 138:147508


REFERENCE 7: 138:147482

REFERENCE 8: 138:147418

REFERENCE 9: 138:66247

REFERENCE 10: 138:61310

PAGE 1-A



L10 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 144701-48-4 REGISTRY

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(1,4'-dimethyl-2'-propyl[2,6'-bi-1H-benzimidazol]-1'-yl)methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 4'-[[4-Methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolylmethyl]-2-biphenylcarboxylic acid

CN B1BR 277

CN B1BR 277SE

CN Micardis

CN Pritor

CN Telmisartan

FS 3D CONCORD

MF C33 H30 N4 O2


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPATZ, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

156 REFERENCES IN FILE CA (1962 TO DATE)

157 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:226765

L10 ANSWER 4 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 144689-24-7 REGISTRY

CN 1H-Imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Olmesartan


CN RNH 6270

FS 3D CONCORD

MF C24 H26 N6 O3

SR CA

LC STN Files: ADISINSIGHT, BIOSIS, CA, CAPLUS, DRUGPAT, DRUGUPDATES, IPA, PROMT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

21 REFERENCES IN FILE CA (1962 TO DATE)

21 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:226765

REFERENCE 2: 138:158871

REFERENCE 3: 138:130974

REFERENCE 4: 138:130810

REFERENCE 5: 137:358176

REFERENCE 6: 137:304828

REFERENCE 7: 137:11015

REFERENCE 8: 137:440

REFERENCE 9: 136:128768

REFERENCE 10: 135:338594

L10 ANSWER 3 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 2: 138:215317

REFERENCE 3: 138:198540

REFERENCE 4: 138:163224

REFERENCE 5: 138:158871

REFERENCE 6: 138:130848

REFERENCE 7: 138:100631

REFERENCE 8: 138:82835

REFERENCE 9: 138:44566

REFERENCE 10: 138:19309

L10 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 139481-59-7 REGISTRY

CN 1H-Benzimidazole-7-carboxylic acid, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 2-Ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid

CN Candesartan

CN Candesartan M1

CN CV 11974

FS 3D CONCORD


MF C24 H20 N6 O3

CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMLIST, CIN, DIOGENES, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PROMT, TOXCENTER, USAN, USPATZ, USPATFULL

(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

327 REFERENCES IN FILE CA (1962 TO DATE)

5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

330 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:243276

REFERENCE 2: 138:236216

REFERENCE 3: 138:226765

REFERENCE 4: 138:215317

REFERENCE 5: 138:214718

REFERENCE 6: 138:214716


REFERENCE 7: 138:214715

REFERENCE 8: 138:214714

548/252

L10 ANSWER 5 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)
 REFERENCE 9: 138:214713
 REFERENCE 10: 138:198384

L10 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2003 ACS
 RN 138402-11-6 REGISTRY
 CN 1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(1H-tetrazol-5-yl)][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 2-Butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one
 CN Aprovel
 CN Avapro
 CN BMS 186295
 CN Irbesartan
 CN Karvea
 CN SR 47436
 FS 3D CONCORD
 MF C25 H28 N6 O
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

362 REFERENCES IN FILE CA (1962 TO DATE)
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 364 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:243276


REFERENCE 2: 138:231534

REFERENCE 3: 138:231507

L10 ANSWER 6 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)
 REFERENCE 4: 138:226765
 REFERENCE 5: 138:215317
 REFERENCE 6: 138:214768
 REFERENCE 7: 138:214713
 REFERENCE 8: 138:198354
 REFERENCE 9: 138:175664
 REFERENCE 10: 138:162849

L10 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2003 ACS
 RN 137862-53-4 REGISTRY
 CN L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN CGP 48933
 CN Diovan
 CN Nisls
 CN Tareq
 CN Valsartan
 FS STEREOSEARCH
 DR 186597-74-0
 MF C24 H29 N5 O3
 CI COM
 SR CA
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

368 REFERENCES IN FILE CA (1962 TO DATE)
 3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 372 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:243276

REFERENCE 2: 138:231535

REFERENCE 3: 138:226765

L10 ANSWER 7 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 4: 138:226705

REFERENCE 5: 138:215702

REFERENCE 6: 138:215317

REFERENCE 7: 138:214713

REFERENCE 8: 138:158871

REFERENCE 9: 138:130789

REFERENCE 10: 138:89813

L10 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 133040-01-4 REGISTRY

CN 2-Thiophenepropanoic acid, .alpha.-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-. (.alpha.E)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 2-Thiophenepropanoic acid, .alpha.-[[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazol-5-yl]methylene]-. (E)-

OTHER NAMES:

CN (E)-2-Butyl-1-(p-carboxybenzyl)-.alpha.-2-thenylimidazole-5-acrylic acid

CN Eprosartan

CN SKB 108566

CN SKF 108566

FS STEREOSearch

MF C23 H24 N2 O4 S

CI COM


SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMINFORMRX, CIN, DIOGENES, DRUGNL, DRUGPAT, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

200 REFERENCES IN FILE CA (1962 TO DATE)

201 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:215317

REFERENCE 2: 138:158871

REFERENCE 3: 138:100632

L10 ANSWER 8 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 4: 138:100631

REFERENCE 5: 138:83116

REFERENCE 6: 138:213

REFERENCE 7: 137:380012

REFERENCE 8: 137:358176

REFERENCE 9: 137:358120

REFERENCE 10: 137:257397

L10 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2003 ACS

RN 114798-26-4 REGISTRY

CN 1H-imidazole-5-methanol, 2-butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)][1,1'-biphenyl]-4-yl]methyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN DUP 89

CN Lortaan

CN Losartan

FS 3D CONCORD

MF C22 H23 Cl N6 O


CI COM

SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CIN, CSChem, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, MEDLINE, MRCK*, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL

(*File contains numerically searchable property data)

Other Sources: WHO



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1456 REFERENCES IN FILE CA (1962 TO DATE)

15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1459 REFERENCES IN FILE CAPLUS (1962 TO DATE)

REFERENCE 1: 138:243419

REFERENCE 2: 138:243276

REFERENCE 3: 138:235485

REFERENCE 4: 138:231516

REFERENCE 5: 138:231504

REFERENCE 6: 138:226854

REFERENCE 7: 138:226765

REFERENCE 8: 138:226705

10/031.398

Page 22


L10 ANSWER 9 OF 9 REGISTRY COPYRIGHT 2003 ACS (Continued)

REFERENCE 9: 138:215317

REFERENCE 10: 138:215254

1997:405439 Document No. 127:39817 Pharmaceutical compositions containing imidazopyridines as **angiotensin II** antagonists.
 Sekine, Yasuo; Kawanishi, Eiki; Narita, Hiroshi; Hashimoto, Yoshihiro; Mizobe, Masakazu (Tanabe Seiyaku Co., Ltd., Japan). Jpn. Kokai Tokkyo Koho JP 09110691 A2 19970428 Heisei. 7 pp. (Japanese). CODEN: JKXXAF.
 APPLICATION: JP 1995-267560 19951017.

GI



AB Pharmaceutical compns., useful for treatment and/or prevention of
 hypertension, nephritis, diabetic nephritis, primary aldosteronemia,
 atherosclerosis, dementia, cerebral circulation disorder, chronic heart
 failure, and angina pectoris, contain imidazopyridines I (R1, R3, R4 =
 lower alkyl; R2 = lower alkanoyl; R3R4 may form C3-6 alkylene) or their
 pharmacol. acceptable salts as active ingredients. I are easily absorbed
 by digestive tract and converted into active forms. I (R1 = Pr, R2 = Ac,
 R3 = R4 = Et) HCl salt (II) at 0.3 mg/kg i.d. suppressed 61.6%
angiotensin II-induced hypertension in dogs. LD50 of II

1996:319527 Document No. 125:25882 ME3221, a surmountable angiotensin AT1-receptor antagonist, prevents hypertensive complications in aged stroke-prone spontaneously hypertensive rats. Nagura, Jun; Hui, Chen; Yamamoto, Mikio; Yasuda, Sumie; Abe, Mitsuhiro; Hachisu, Mitsugu; Konno, Fukio (Pharmaceutical Res. Center, Meiji Seika Kaisha, Ltd., Yokohama, 222, Japan). Japanese Journal of Pharmacology, 71(1). 39-49 (English) 1996. CODEN: JJPAAZ. ISSN: 0021-5198. Publisher: Japanese Pharmacological Society.

AB The protective effects of ME3221, 3-methoxy-2,6-dimethyl-4-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methoxy]pyridine, on aged (32-wk-old) stroke-prone spontaneously hypertensive rats (SHRSP) were studied following long-term (for 8 mo) oral administration. At a dose of 10 mg/kg/day, ME3221 suppressed the mortality and the hypertensive complications obsd. in control SHRSP: **cerebral apoplexy** (hemorrhage, and spongeform and malacia in the cerebral cortex), increased proteinuria, and total N-acetyl-.beta.-D-glucosaminidase activity, and cardiac hypertrophy and pleural effusion. The protective activity of ME3221, a surmountable angiotensin AT1-receptor antagonist, was comparable to losartan, an insurmountable AT1-antagonist, and also to enalapril, an angiotensin-converting enzyme inhibitor. In addn. ME3221 reduced the systolic blood pressure more effectively than the two ref. drugs.

- 1993:462704 Document No. 119:62704 Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. Stier, Charles T., Jr.; Adler, Lawrence A.; Levine, Seymour; Chander, Praveen N. (Dep. Pharmacol., New York Med. Coll., Valhalla, NY, 10595, USA). Journal of Hypertension, 11(3), S37-S42 (English) 1993. CODEN: JOHYD3. ISSN: 0263-6352.
- AB Treatment with the **angiotensin II** antagonist losartan at 30 mg/kg/day, orally, delayed the development of severe hypertension and prevented stroke in saline-drinking stroke-prone spontaneously hypertensive rats (SHRSP); doses of 10 mg/kg/day did not affect the hypertension but prevented the occurrence of **cerebrovascular** lesions until age .gtoreq.28 wk. These and other data are consistent with the theory that **angiotensin II** has an effect on the pathophysiol. of **cerebrovascular** lesion development in saline-drinking SHRSP and that losartan protects against such development in the absence of a blood pressure fall.